Early 3-day course of remdesivir for the prevention of the progression to severe COVID-19 in the elderly: A single-centre, real-life cohort study.

Publication date: Oct 01, 2023

Remdesivir, a viral RNA polymerase inhibitor, has constituted a key component of therapeutic regimens against the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Originally approved for administration in hospitalized patients, remdesivir leads to improved outcomes in patients with moderate to severe coronavirus disease 2019 (COVID-19). After proving to be effective in hospitalized patients, its use gained approval in early-stage disease for symptomatic outpatients who are at a high risk of progression to severe disease. The present study is a real-life prospective cohort study involving 143 elderly non-hospitalized patients with SARS-CoV-2 (≥65 years of age) who attended the emergency department of the authors’ hospital seeking care for COVID-19 symptoms appearing within the prior 7 days. Eligible patients received intravenous remdesivir at a dose of 200 mg on the first day and 100 mg on days 2 and 3. The efficacy endpoints were set as the need for COVID-19-related hospitalization and all-cause mortality in the following 28 days. A total of 143 patients participated in the study. Of these patients, 118 (82. 5%) patients were vaccinated with at least two doses. All patients enrolled completed the 3-day course, with a total of 6 out of 143 patients (4. 2%) having a COVID-19-related hospitalization by day 28, and 5 patients (3. 5%) succumbing to the disease within the study period. In the univariate Cox regression analysis, the neutrophil-to-lymphocyte ratio and haematological malignancy were identified as predictors of progression to severe disease, and albumin levels, the C-reactive protein-to-albumin ratio (CAR) and haematological malignancy were identified as predictors of 28-day mortality. On the whole, the findings of the present study demonstrated that among the elderly outpatients, a 3-day course of intravenous remdesivir was associated with favourable outcomes.

Concepts Keywords
Authors coronavirus disease 2019
Coronavirus elderly
Early immunocompromised
Elderly pneumonia
Hospitalization remdesivir


Type Source Name
disease MESH COVID-19
pathway KEGG RNA polymerase
disease VO effective
disease MESH emergency
disease VO dose
disease VO vaccinated
disease MESH malignancy
disease MESH pneumonia

Original Article

(Visited 1 times, 1 visits today)